Cyclacel Q2 2023 net loss $5.4M; cash $10.2M, runway to end of 2023

Bio Green Med Solution, Inc.

2023-Q2 EPS reported -$0.91 revenue$373,000

Net loss of $5.4M for Q2 2023 vs $4.6M Q2 2022; cash $10.2M at June 30, 2023 (down from $18.3M Dec 2022).
R&D expenses $4.7M in Q2 2023 vs $4.2M Q2 2022; fadraciclib $3.0M, plogosertib $1.4M.
Cash expected to fund programs through end of 2023; discretionary cuts could extend to Q2 2024.
Phase 1/2 data for fadraciclib and plogosertib expected in 2023; tumor shrinkage observed in several cancer types.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Bio Green Med Solution, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $5.4 million.

Period: second quarter ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023, was $5.4 million
Result: reported results

Exact text from the filing

Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bio Green Med Solution, Inc. reported financial results for six months ended June 30, 2023.

Period: six months ended June 30, 2023
Result: reported results

Exact text from the filing

Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.